ArticleNeurology. Genetics2026
Gene Expression Profiles at Early vs Late Stages After Cervical Artery Dissection.
Article in Neurology. Genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Cervical artery dissection (CeAD) is a common cause of stroke in young adults. While the pathogenesis of CeAD remains poorly understood, clinical and genetic associations suggest a systemic arteriopathy at the early phase of CeAD. We hypothesize that individuals experiencing CeAD express a distinct gene expression profile at the early phase compared with (1) age-matched and sex-matched controls and (2) late-phase profiles within the same individual at a later time point. Methods: We prospectively enrolled patients (n = 37) with CeAD with and without ischemic stroke (IS) from 2014 to 2016, excluding cases of significant trauma or known monogenic connective tissue disease. We compared CeAD cases with non-CeAD IS cases (n = 16) and healthy controls (n = 11). Study personnel collected blood samples within 4 weeks of the event and again at a 3-6-month follow-up. We assessed gene expression using microarray analysis at the time of CeAD, relative to controls and >3-month follow-up samples within CeAD cases. We applied a mixed-effects regression model that included covariates of age, sex, race/ethnicity, time of enrollment, and stroke occurrence. We used a false discovery rate (FDR) cutoff of 5% and a 1.5-fold change cutoff to identify robust differential expression. Results: Within early-phase CeAD cases, 1,238 genes showed differential expression at a 5% FDR compared with late-phase profiles, with 31 genes exhibiting at least a 1.5-fold change. We identified 538 differentially expressed genes between patients with CeAD and controls, of which 30 reached the 1.5-fold threshold. Comparison of late-phase profiles with controls revealed 11 differentially expressed genes. Gene ontology highlighted that 7 of the 11 genes were associated with hemoglobin metabolism. Discussion: In this preliminary gene expression analysis of patients with CeAD, we identified a distinct gene expression profile associated with early-phase dissection. The predominance of differential gene expression related to hemoglobin metabolism warrants further study and replication in independent cohorts of patients with arterial dissection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.